Nichols & Pratt Advisers LLP MA Grows Position in Novo Nordisk A/S $NVO

Nichols & Pratt Advisers LLP MA lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 500,991 shares of the company’s stock after acquiring an additional 8,935 shares during the period. Novo Nordisk A/S makes up 1.8% of Nichols & Pratt Advisers LLP MA’s investment portfolio, making the stock its 22nd biggest position. Nichols & Pratt Advisers LLP MA’s holdings in Novo Nordisk A/S were worth $27,800,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of NVO. True Wealth Design LLC lifted its stake in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the last quarter. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $25,000. NewSquare Capital LLC raised its position in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. bought a new stake in Novo Nordisk A/S in the second quarter valued at $37,000. Finally, Steigerwald Gordon & Koch Inc. bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $39,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on NVO shares. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. The Goldman Sachs Group reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 29th. Citigroup began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, Jefferies Financial Group began coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $57.79.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $59.01 on Tuesday. The firm has a 50 day moving average of $53.72 and a 200 day moving average of $54.28. The firm has a market capitalization of $263.46 billion, a price-to-earnings ratio of 17.15 and a beta of 0.66. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The firm had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.